Southern China hit by outbreak of mosquito-borne infection chikungunya
Chikungunya fever cases jumped to 4,014 on Friday, representing a rapid rise in numbers since authorities started tracking cases two weeks ago, according to public records released by health departments in districts in Foshan. The city in China's southern province Guangdong has been heavily impacted by the surge in infections.
The chikungunya outbreak remains 'quite severe,' Sun Yang, deputy director of the National Center for Disease Control and Prevention, said at a news conference on Wednesday in Foshan.
Chikungunya is spread to people by the bites of infected mosquitoes. It causes fever and severe joint pain, but deaths are rare, according to the World Health Organization.
The Chinese Center for Disease Control and Prevention has issued various advisories on how to prevent chikungunya fever and dengue fever, a similar disease also spread by mosquitoes. Physical protection barriers, such as screen doors, mosquito nets for beds and mosquito repellent on exposed skin, was recommended. It said that the epidemic was 'imported' without specifying from where.
The Chinese agency also called for people who have symptoms like fever, rash and joint pain to see a doctor.
Shunde district in Foshan, where 90% of the cases are located, is famous for its Cantonese food, and sees many visitors each year.
Patients who tested positive for chikungunya fever stayed in hospital beds covered by mosquito nets, according to photos shown on state-run broadcaster CCTV.
Local media reports said on Thursday that local authorities had almost doubled the number of mosquito-proof isolation beds to 7,220 to meet the growing demand.
Authorities in Guangdong are urging residents to make sure there's no standing water in their homes, such as in flowerpots, coffee machines or spare bottles. The Health Commission in Foshan stated on Thursday that a fine of up to 10,000 yuan ($1,400) could be applied if violations are found.
The Beijing CDC said on Tuesday that the city occasionally experiences imported cases of chikungunya fever.
There are two chikungunya vaccines that have received regulatory approvals in several countries and/or have been recommended for use in populations at risk, but the vaccines are neither widely available nor in widespread use, according to WHO.
China had its first chikungunya spike in 2010 with 253 cases in Dongguan, a nearby city in the same province, according to the Guangdong provincial CDC. Several cases were found in years since then, but they weren't widespread.
The country's first case was imported in 1987, according to research papers and media reports.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc.
Pfizer Inc. (NYSE:PFE) is among the . On July 24, 2025, Pfizer Inc. (NYSE:PFE) finalized the global licensing agreement with 3SBio, Inc. With this agreement, PFE acquired the exclusive rights to develop, manufacture, and commercialize 3SBio's SSGJ-707, a bispecific antibody for PD-1 and VEGF. Leveraging 3SBio's proprietary CLF2 platform, this innovative treatment enhances Pfizer's oncology pipeline and solidifies its competitive edge in cancer research. The antibody is presently undergoing clinical trials in China for non-small cell lung cancer (NSCLC) with promising interim Phase 2 results. It is also under clinical trials for gynecological tumors. By manufacturing the drug in the U.S. and expanding clinical trials globally, Pfizer Inc. (NYSE:PFE) aims to focus on Phase 3 studies for NSCLC and other solid tumors. Pfizer Inc. (NYSE:PFE) will make an upfront payment of $1.25 billion to 3SBio and acquire a $100 million equity stake, as per the agreed terms. With up to $150 million in potential payments, Pfizer Inc. (NYSE:PFE) can exercise the option to extend the agreement for exclusive rights in China. Operating globally, Pfizer Inc. (NYSE:PFE) discovers, develops, and sells biopharmaceuticals. It is one of the best ESG stocks. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
People Are Reporting A Frightening COVID Symptom — Here's What To Know
A positive COVID-19 test result is not something that anyone wants to see — but now there may be an extra reason to avoid getting sick. COVID infections cause miserable symptoms such as fever, fatigue, congestion and more. Now, though, some people infected with COVID in China are reporting a very sore throat that's been nicknamed 'razor blade throat.' According to Google trends data, people throughout the U.S. are now, too, worried about this scary-sounding symptom and are searching for things like 'new covid variant painful symptom' and 'covid razor throat.' Just how worried do you need to be about a super-painful sore throat during a COVID infection? Below, doctors weigh in on the supposed 'razor blade' sore throat symptom: Some people with COVID are reporting a 'razor blade throat,' but you don't need to panic. It's nothing new. 'In the past, as new variants have come on the scene, there almost invariably have been questions about distinctive symptoms, and after a while, when you gather a lot of data, turns out not to be the case — all of these symptoms have occurred before,' said Dr. William Schaffner, a professor of preventive medicine in the department of health policy at Vanderbilt University Medical Center in Nashville, Tennessee. Meaning, the circulating COVID variants tend to produce the same sort of symptoms and disease as the ones from years ago, Schaffner added. 'Although the more recent variants, these omicron variants, are less severe,' he said. A very sore throat isn't specific to the circulating COVID variants, said Dr. Carrie Horn, the chief medical officer and chief of the division of hospital and internal medicine at National Jewish Health in Colorado. Instead, it's a symptom that has been associated with COVID infections for a while, Horn said. Schaffner had not heard of the 'razor blade' sore throat symptom particularly, but has heard of people having a severe sore throat with COVID infections. While some people can have a very sore throat that could be described as razor-like, it doesn't mean it's going to happen to everyone — and it also isn't some new, scary symptom that is associated with new COVID infections. There is not one outstanding COVID symptom that marks an infection, said Dr. Mark Burns, an infectious disease expert at UofL Health in Louisville, Kentucky. 'A sore throat is a symptom of this, but also fever and cough and fatigue, these are all symptoms as well,' Burns added. 'To sum it all up, the symptoms, including sore throat, are really no different. There's no increased intensity based on sore throat or anything like that,' added Burns. Here's how you can protect yourself from a COVID infection: COVID tends to surge twice a year — once in the winter and once in the mid-to-late summer, Schaffner said. 'And so there has been a longstanding recommendation by the CDC's Advisory Committee on Immunization Practices that people who are at increased risk of getting severe COVID should actually get two COVID vaccinations a year. Obviously, one in the fall to prevent the winter increase, but another right now in order to help prevent serious disease during the late summer and early fall,' Schaffner said. This goes for people 65 and older, younger people with underlying chronic medical conditions and pregnant people, he said. 'The recommendation is take special precautions and get that extra dose, because if we get infected ... we get that extra protection and to help keep us out of the hospital,' Schaffner said. Wearing a mask in indoor spaces, social distancing, washing your hands often and increasing ventilation when possible are more ways to protect yourself from COVID and other respiratory viruses, too, said Burns. If you do get sick, there are treatments available. If you have any COVID symptoms, such as sore throat, fatigue, cough or fever, take a test to see if you have COVID. If you are infected, get in touch with your doctor, particularly if you're high-risk as there are treatments available, said Schaffner. It's important that you talk to your primary care provider as the guidance will vary depending on your age, underlying conditions and other risk factors. COVID is a miserable infection, Horn added. 'Over-the-counter meds help — Ibuprofen alternating with Tylenol, if you're able to take those ... there's no reason to be miserable,' Horn said. 'So, take the medicine that you are able to take to help,' she said. It's also important to stay hydrated when you're sick even if you do have a painful sore throat. A sore throat can make hydration feel like more of a chore, but it's important to drink water and herbal teas as dehydration can further irritate the dry membranes in your throat, Horn said. 'If you are sick, it's best to keep your germs to yourself,' said Horn. This means canceling the dinner plans, not going to the party and calling out of work if you can — if you can't, wearing a tight-fitting mask is key, Horn added. 'Preventing transmission is the biggest thing that we can do to help keep everybody healthy,' Horn said. Related... A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms RFK Jr. Wants To Take COVID Shots Away From Pregnant People — But You Can Fight Back CDC Changes COVID Vaccine Recommendations — But Doesn't Go As Far As RFK Jr. Wanted
